A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

被引：2

作者：

Sun, Mingyuan ^{[1
]}

Qi, Junyuan ^{[1
]}

Chen, Zi ^{[2
]}

Zhang, Hongli ^{[2
]}

Song, Yongping ^{[3
]}

Shen, Aizong ^{[4
]}

Liu, Huilan ^{[4
]}

Huang, Jianying ^{[5
]}

Zhou, Fuling ^{[5
]}

Jin, Jie ^{[6
]}

Lu, Ming ^{[7
]}

Ahmad, Mohammad ^{[7
]}

Men, Lichuang ^{[2
]}

Cen, Wan ^{[2
]}

Yang, Dajun ^{[2
,8
]}

Wang, Jianxiang ^{[1
]}

Zhai, Yifan ^{[2
,7
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China

[3] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[4] USTC Anhui Prov Hosp, Affiliated Hosp 1, Hefei, Peoples R China

[5] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China

[6] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[7] Ascentage Pharma Grp Inc, Rockville, MD USA

[8] Sun Yat Sen Univ, State Key Lab Oncol South China Collaborat Innova, Canc Ctr, Guangzhou, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152235

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3730

引用

页码：3730 / +

页数：4

共 50 条

[31] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Koji Izutsu
Kazuhito Yamamoto
Koji Kato
Takayuki Ishikawa
Noriko Fukuhara
Yasuhito Terui
Ilseung Choi
Kathryn Humphrey
Su Young Kim
Sumiko Okubo
Natsumi Ogawa
Yasuko Nishimura
Ahmed Hamed Salem
Dai Maruyama
International Journal of Hematology, 2021, 113 : 370 - 380
[32] An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies
Zheng Weiwei
Zhou Hui
Xi Zhang
Jing Hongmei
Zhou Dongmei
Zhou Fang
Gao Li
Wan Wei
Song Yaobo
Yan, Haung
Xu Linfeng
Hu Yonghan
Le Meijie
Qi Junyuan
Qiu, Lugui
BLOOD, 2022, 140 : 9353 - 9355
[33] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Darden, David E.
Gressick, Lori A.
Nolan, Cathy E.
Yang, Jianning
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[34] Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib
Tam, Constantine S.
Verner, Emma
Lasica, Masa
Arbelaez, Alejandro
Browett, Peter J.
Soumerai, Jacob D.
Hilger, James
Fang, Yiqian
Huang, Jane
Simpson, David
Opat, Stephen
Cheah, Chan Yoon Y.
BLOOD, 2021, 138
[35] PRELIMINARY SAFETY AND EFFICACY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES TREATED WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 IN MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB
Ghia, P.
Tam, C.
Verner, E.
Lasica, M.
Arbelaez, A.
Browett, P.
Soumerai, J.
Hilger, J.
Fang, Y.
Huang, J.
Simpson, D.
Opat, S.
Cheah, C.
HAEMATOLOGICA, 2022, 107 : 33 - 34
[36] Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.
Dudek, Arkadiusz Z.
Juric, Dejan
Dowlati, Afshin
Seymour, Erlene Kuizon
Ahnert, Jordi Rodon
Wang, Bingxia
Huszar, Dennis
Berger, Allison J.
Friedlander, Sharon
Gomez-Pinillos, Alejandro
Proscurshim, Igor
Olszanski, Anthony J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
Kastritis, Efstathios
Matous, Jeffrey, V
Abro, Emad Uddin
Eves, P. Taylor
Zheng, Cheng
Fiorino, Tony
Berdeja, Jesus
BLOOD, 2022, 140 : 4438 - 4439
[38] A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.
Lakhani, Nehal J.
Rasco, Drew W.
Tolcher, Anthony W.
Huang, Yingjie
Ji, Jiao
Wang, Hengbang
Dong, Qi
Men, Lichuang
O'Rourke, Timothy J.
Chandana, Sreenivasa R.
Amaya, Alex
Cole, Yvette
Kaiser, Brianne
Mays, Theresa A.
Patnaik, Amita
Papadopoulos, Kyriakos P.
Yang, Dajun
Zhai, Yifan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[39] Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
Khawaja, M. Rizwan Rizwan-Ul-Haq
Naqash, Abdul Rafeh
Schneider, Reva
Shastri, Aditi
Stahl, Maximilian
Moser, Justin C.
Karim, Nagla Fawzy Abdel
Madanat, Yazan
Jonas, Brian Andrew
Stein, Eytan
Gadgeel, Shirish M.
McCloskey, James K.
Gollerkeri, Ashwin
Perea, Rachelle
Chutake, Yogesh
Agarwal, Sagar
Henrick, Patrick
Shi, Kelvin
Daver, Naval Guastad
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma Harbouring t(11;14): Phase 1b/2 study
Crescenzo, Rocco
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 63 - 63

← 1 2 3 4 5 →